- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Looking Ahead in ITP: Addressing Unmet Needs and Embracing Innovation
A panelist discusses how personalized ITP care requires open conversations about testing costs, insurance coverage, and treatment accessibility, with clinicians helping patients navigate financial barriers through pharmaceutical assistance programs and clinical trials.
EP: 1.Understanding Immune Thrombocytopenia: Pathophysiology, Classification, and Differentiation
EP: 2.Diagnostic and Patient Education Strategies in ITP
EP: 3.Managing Bleeding Risk in Patients with ITP
EP: 4.Living with ITP: Impact of Fatigue and Other Symptoms on Patients’ Quality of Life
EP: 5.Tailoring Care in ITP Through a Health Equity Lens
EP: 6.Looking Ahead in ITP: Addressing Unmet Needs and Embracing Innovation
Personalized care for ITP patients must consider financial barriers, as diagnostic testing can be expensive. Healthcare providers should maintain open communication regarding which tests are essential for confident diagnosis, which may not be covered by insurance, and what alternatives exist for patients with limited or no coverage.
Physicians should discuss all available treatment options honestly while considering accessibility factors. Support mechanisms include assistance from the clinical office, ITP support organizations, pharmaceutical company programs, and clinical trials that may cover both diagnostic and therapeutic interventions when traditional options are financially out of reach.
While discussing financial aspects of care isn't comfortable for many physicians, the current healthcare climate demands understanding potential barriers to access. Open dialogue about testing costs, copay concerns, and payment responsibilities allows healthcare teams to help patients navigate these challenges and receive appropriate care for their condition.
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More
